Author: Rachel Tan

Rachel is a marketing graduate from the National University of Singapore. She enjoys researching and writing extensively on healthcare, medicine, and technology in her personal time. In her free time, she enjoys reading books on psychology, science-related mysteries, and documentaries as a personal interest.

A new oral option for moderate-to-severe plaque psoriasis has emerged. Clinical trials show deucravacitinib delivering stronger efficacy than apremilast, offering a fresh approach after nearly a decade without major oral treatment innovation.

Log In or Register as a healthcare professional to read the full article.

Read More